Lilly pays up to $1B for AlzeCure's small-molecule Alzheimer's candidate; Bial drops Parkinson's drug after Phase 2b miss; Parabilis boosts IPO target to $553M net proceeds.
Plus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Parabilis Medicines, the decade-old and well-funded
If Parabilis follows through with its plans, that would make it one of the largest biotech IPOs of the past few years and the…
Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug…
As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a…
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in…
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere,…
